EUVIMEDEUVIMED entdecken
Vergleichsstudie

Choosing the optimal therapy for metastatic renal cell carcinoma: Insights from a real‐world comparative study

Takuto Hara iD, Jun Teishima iD, Yasuyoshi Okamura, Kotaro Suzuki iD, Yukari Bando iD, Tomoaki Terakawa iD, Koji Chiba, Yoji Hyodo iD, Hideaki Miyake

International Journal of Urology · 2025

DOI: 10.1111/iju.15590 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Journal of Urology, 2025. Verfasst von Takuto Hara und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Protein Kinase Inhibitors, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The evolution of combination therapies integrating immune checkpoint inhibitors has revolutionized the first‐line treatment of metastatic renal cell carcinoma (mRCC). Although these therapies are clinically approved, direct comparisons between dual immune checkpoint inhibitors (IOIO) and immune checkpoint inhibitors combined with tyrosine kinase inhibitors (IOTKI) in clinical trials are lacking. This gap creates uncertainties in selecting the most appropriate treatment based on patient‐specific factors.

Methods

This study employed the inverse probability of treatment weighting (IPTW) method to analyze progression‐free survival (PFS) and overall survival (OS) for patients with mRCC receiving IOIO or IOTKI treatment regimens.

Results

A total of 171 patients were analyzed after applying inclusion criteria and propensity scoring. The study found no significant differences in PFS and OS between the two treatment modalities in the IPTW cohort. However, subgroup analyses revealed that IOTKI therapy was associated with better PFS and OS for patients without bone metastases and better OS for patients with a body mass index (BMI) over 25. IOIO therapy showed better OS for patients with a BMI below 18.5.

Conclusion

Both IOIO and IOTKI therapies were effective. Therapy selection could be better tailored to patient characteristics by including factors such as the presence of bone metastases and BMI. This study enhances understanding of how patient‐specific factors interact with different treatment modalities, potentially guiding more personalized treatment decisions in clinical practice for mRCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsProtein Kinase InhibitorsImmune Checkpoint InhibitorsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAgedProgression-Free SurvivalRetrospective StudiesPropensity ScoreBone NeoplasmsBody Mass IndexAdult

Stichwörter der Autor:innen

immune checkpoint inhibitorsmetastatic renal cell carcinomamolecular target drug

Substanzen

Protein Kinase InhibitorsImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.

ORCID-Profile: Takuto Hara, Jun Teishima, Kotaro Suzuki, Yukari Bando, Tomoaki Terakawa, Yoji Hyodo

Zitieren

APA

Hara, T., Teishima, J., Okamura, Y., Suzuki, K., Bando, Y., Terakawa, T., Chiba, K., Hyodo, Y., & Miyake, H. (2025). Choosing the optimal therapy for metastatic renal cell carcinoma: Insights from a real‐world comparative study. International Journal of Urology. https://doi.org/10.1111/iju.15590

Vancouver

Hara T, Teishima J, Okamura Y, Suzuki K, Bando Y, Terakawa T, et al. Choosing the optimal therapy for metastatic renal cell carcinoma: Insights from a real‐world comparative study. International Journal of Urology. 2025. doi:10.1111/iju.15590

BibTeX
@article{Hara2025,
  author = {Hara, Takuto and Teishima, Jun and Okamura, Yasuyoshi and Suzuki, Kotaro and Bando, Yukari and Terakawa, Tomoaki and Chiba, Koji and Hyodo, Yoji and Miyake, Hideaki},
  title = {Choosing the optimal therapy for metastatic renal cell carcinoma: Insights from a real‐world comparative study},
  journal = {International Journal of Urology},
  year = {2025},
  doi = {10.1111/iju.15590}
}
Kostenlos starten →